<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01097447</url>
  </required_header>
  <id_info>
    <org_study_id>CXL (2)</org_study_id>
    <nct_id>NCT01097447</nct_id>
  </id_info>
  <brief_title>Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas (2)</brief_title>
  <official_title>Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cxlusa</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cxlusa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of ultraviolet-A (UVA)-induced cross-linking of corneal collagen
      (CXL) as a method to increase the biomechanical and biochemical stability of the cornea by
      inducing additional cross-links within or between collagen fibers using UVA light and the
      photo- mediator riboflavin. The purpose of this study is to generate data for presentation at
      medical meetings and for peer-review publication
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Increase the biomechanical and biochemical stability of the cornea by inducing additional cross-links within</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>increase the biomechanical and biochemical stability of the cornea between collagen fibers using UVA light and the photo- mediator riboflavin</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Keratoconus</condition>
  <condition>Ectasia</condition>
  <condition>Degeneration</condition>
  <arm_group>
    <arm_group_label>Ciprofloxicine or Vigamox or other</arm_group_label>
    <description>up to qid till epithelialized.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical Nonsteroidal (Acular, Acuvail, Voltaren Xibrom</arm_group_label>
    <description>up to qid for up to 5-10 days postop</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical steroid (FML, Pred Forte, Flarex</arm_group_label>
    <description>qid for up to 8 weeks</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinic
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  8 years of age or older

          -  Diagnosis of keratoconus, post-LASIK ectasia, or pellucid marginal degeneration or
             forme fruste pellucid marginal degeneration.

          -  Diagnosis of FFKC

          -  History of Radial Keratotomy with fluctuating vision.

          -  Ability to provide written informed consent

          -  Likely to complete all study visits

          -  Minimum corneal thickness of at least 300 measured by ultrasound or Pentacam

        Exclusion Criteria:

          -  Severe corneal scarring that markedly affects vision

          -  Contraindications to any study medications or their components

          -  Pregnancy or breast feeding

          -  Active Herpes Corneal Disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Parag Majmudar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chicago Cornea Consultants, LTD</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lance Forstot, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Corneal Consultants of Colorado, P.C</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bradley Bowman, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cornea Associates of Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sandy Feldman, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clear View Eye &amp; Laser Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sherman Reeves, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Minnesota Eye Consultants, P.A.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Debi Graveman</last_name>
    <phone>314 966-3377</phone>
    <email>dg@cxlusa.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clear View Eye &amp; Laser Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Corneal Consultants of Colorado, P.C</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chicago Cornea Consultants, LTD</name>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Minnesota Eye Consultants, P.A.</name>
      <address>
        <city>Bloomington</city>
        <state>Minnesota</state>
        <zip>55431</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cornea Associates of Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2010</study_first_submitted>
  <study_first_submitted_qc>March 31, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2010</study_first_posted>
  <last_update_submitted>February 1, 2017</last_update_submitted>
  <last_update_submitted_qc>February 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diagnosis of keratoconus, post-LASIK ectasia, FFKC, or pellucid marginal degeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
    <mesh_term>Dilatation, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

